The FRESH study

• Verfasst von: Vollherbst, Dominik [VerfasserIn]
• Verfasst von: Lücking, H. [VerfasserIn]
• Verfasst von: DuPlessis, J. [VerfasserIn]
• Verfasst von: Sonnberger, M. [VerfasserIn]
• Verfasst von: Maurer, C. [VerfasserIn]
• Verfasst von: Kocer, N. [VerfasserIn]
• Verfasst von: Killer-Oberpfalzer, M. [VerfasserIn]
• Verfasst von: Rautio, R. [VerfasserIn]
• Verfasst von: Valvassori, L. [VerfasserIn]
• Verfasst von: Berlis, A. [VerfasserIn]
• Verfasst von: Gasser, S. [VerfasserIn]
• Verfasst von: Gatt, S. [VerfasserIn]
• Verfasst von: Dörfler, A. [VerfasserIn]
• Verfasst von: Bendszus, Martin [VerfasserIn]
• Verfasst von: Möhlenbruch, Markus Alfred [VerfasserIn]
• Titel: The FRESH study
• Titelzusatz: treatment of intracranial aneurysms with the new FRED X flow diverter with antithrombotic surface treatment technology - first multicenter experience in 161 patients
• Verf.angabe: D.F. Vollherbst, H. Lücking, J. DuPlessis, M. Sonnberger, C. Maurer, N. Kocer, M. Killer-Oberpfalzer, R. Rautio, L. Valvassori, A. Berlis, S. Gasser, S. Gatt, A. Dörfler, M. Bendszus, and M.A. Möhlenbruch
• E-Jahr: 2023
• Jahr: April 10, 2023
• Umfang: 7 S.
• Fussnoten: Gesehen am 06.06.2023
• Titel Quelle: Enthalten in: American journal of neuroradiology
• Ort Quelle: Oak Brook, Ill. : Soc., 1980
• Jahr Quelle: 2023
• Band/Heft Quelle: 44(2023), 4 vom: Apr., Seite 474-480
• ISSN Quelle: 1936-959X
• DOI: doi:10.3174/ajnr.A7834
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1847476635

Abstract

BACKGROUND AND PURPOSE: Flow diverters with antithrombotic coatings are increasingly used to improve the safety of flow diverter treatments of intracranial aneurysms. This study aimed to investigate the safety and short-term efficacy of the new FRED X flow diverter. - MATERIALS AND METHODS: Medical charts and procedural and imaging data of a consecutive series of patients with intracranial aneurysms who were treated with the FRED X at 9 international neurovascular centers were retrospectively analyzed. - RESULTS: One hundred sixty-one patients (77.6% women; mean age, 55 years) with 184 aneurysms (11.2% acutely ruptured) were included in this study. Most aneurysms were located in the anterior circulation (77.0%), most frequently at the ICA (72.7%). The FRED X was successfully implanted in all procedures. Additional coiling was performed in 29.8%. In-stent balloon angioplasty was necessary in 2.5%. The rate of major adverse events was 3.1%. Thrombotic events occurred in 7 patients (4.3%) with 4 intra- and 4 postprocedural in-stent thromboses, respectively (1 patient had both peri- and postprocedural thrombosis). Of these thrombotic events, only 2 (1.2%) led to major adverse events (ischemic strokes). Postinterventional neurologic morbidity and mortality were observed in 1.9% and 1.2%, respectively. The rate of complete aneurysm occlusion after a mean follow-up of 7.0 months was 66.0%. - CONCLUSIONS: The new FRED X is a safe and feasible device for aneurysm treatment. In this retrospective multicenter study, the rate of thrombotic complications was low, and the short-term occlusion rates are satisfactory.